Clinical Trial Update: A Study of VRG50635 in Participants With Amyotrophic Lateral Sclerosis (ALS) [Phase 1]

View source ↗

Summary

A Phase 1 study of VRG50635 for amyotrophic lateral sclerosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• VRG50635

Snippet

Sponsor: Verge Genomics | Conditions: Amyotrophic Lateral Sclerosis | Phase 1 | Status: TERMINATED